Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Recludix Pharma, Inc.
Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024
August 05, 2024
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting
May 17, 2024
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian
April 23, 2024
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma to Participate in Two Investor Conferences in March
February 28, 2024
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma to Present at Two Investor Conferences in February
February 06, 2024
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma to Present at Two Investor Conferences in November
November 09, 2023
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit
October 31, 2023
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)
October 17, 2023
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma to Participate in Multiple Investor Conferences in September
August 30, 2023
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
July 20, 2023
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Tickers
SNY
Recludix Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference
February 01, 2023
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 06, 2023
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology
October 20, 2022
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Recludix Pharma Announces the Appointment of Senior Executive Matthew S. Caldemeyer as Chief Business Officer
September 29, 2022
From
Recludix Pharma, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.